家庭氧疗对肺动脉高压或慢性血栓栓塞性肺高血压患者运动能力和生活质量的影响:随机安慰剂对照试验
本研究纳入30例静息血氧饱和度≥90%但运动诱发血氧下降的肺动脉高压或慢性血栓栓塞性肺高血压患者,采用双盲交叉设计比较家庭氧疗与安慰剂。结果显示家庭氧疗可改善6分钟步行距离、躯体功能评分及心功能分级,组间差异有统计学意义。
要点
- 家庭氧疗较安慰剂显著提高6分钟步行距离,组间差异18米(P=0.042)。
- 家庭氧疗改善躯体功能评分,组间差异6分(P=0.029)。
- 家庭氧疗显著改善纽约心功能分级,支持开展长期大样本随机试验。
核心结论
- 在伴有运动诱发性低氧血症的PAH/CTEPH患者中,家庭氧疗可改善运动能力、生活质量和功能分级。
研究设计与样本
- 随机、双盲、安慰剂对照交叉试验,纳入30例PAH/CTEPH患者,平均年龄60±15岁,肺动脉压39±11 mmHg。
- 患者静息SpO2≥90%且6分钟步行试验中SpO2下降≥4%,均在使用肺动脉高压靶向药物。
- 家庭氧疗与安慰剂(室内空气)各治疗5周,洗脱期2周;氧疗方式为经鼻导管3 L·min-1,夜间及日间静息时给予。
主要发现
- 家庭氧疗使6分钟步行距离从基线478±113 m平均增加19 m(95%CI 6-32),安慰剂组变化为1 m(95%CI -11-13)。
- 家庭氧疗使躯体功能评分从基线52±29平均增加4分(95%CI 0-8),安慰剂组变化为-2分(95%CI -6-2)。
- 组间变化差异:6分钟步行距离18 m(95%CI 1-35,P=0.042),躯体功能评分6分(95%CI 1-11,P=0.029)。
- 家庭氧疗较安慰剂显著改善纽约心功能分级。
临床怎么用
- 对于静息血氧饱和度≥90%但运动后血氧下降≥4%的PAH/CTEPH患者,可考虑家庭氧疗以改善运动能力和生活质量。
- 家庭氧疗方案可参考夜间及日间静息时经鼻导管3 L·min-1。
局限性
- 样本量较小(30例),治疗周期较短(5周),需大规模长期随机试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: We investigated whether domiciliary oxygen therapy (DOXT) increases exercise capacity and quality of life in patients with pulmonary arterial or distal chronic thromboembolic pulmonary hypertension (PAH/CTEPH) presenting with mild resting hypoxaemia and exercise-induced oxygen desaturation. MATERIALS AND METHODS: 30 patients with PAH/CTEPH, mean±sd age 60±15 years, pulmonary artery pressure 39±11 mmHg, resting arterial oxygen saturation measured by pulse oximetry (S pO2 ) ≥90%, S pO2 drop during a 6-min walk test ≥4%, on pulmonary hypertension-targeted medication, were randomised in a double-blind crossover protocol to DOXT and placebo (ambient air) treatment, each over 5 weeks, at 3 L·min-1 via nasal cannula overnight and when resting during the day. Treatment periods were separated by 2 weeks of washout. Co-primary outcomes were changes in 6-min walk distance (6MWD, breathing ambient air) and physical functioning scale of the 36-item short-form medical outcome questionnaire during treatment periods. RESULTS: DOXT increased the 6MWD from baseline 478±113 m by a mean (95% CI) of 19 (6-32) m, and physical functioning from 52±29 by 4 (0-8) points. Corresponding changes with placebo were 1 (-11-13) m in 6MWD and -2 (-6-2) points in physical functioning. Between-treatment differences in changes were 6MWD 18 (1-35) m (p=0.042) and physical functioning 6 (1-11) points (p=0.029). DOXT significantly improved the New York Heart Association functional class versus placebo. ANSWER TO THE QUESTION: This first randomised trial in PAH/CTEPH patients with exercise-induced hypoxaemia demonstrates that DOXT improves exercise capacity, quality of life and functional class. The results support large long-term randomised trials of DOXT in PAH/CTEPH.
引用
- Ulrich S, Saxer S, Hasler ED, et al. Effect of domiciliary oxygen therapy on exercise capacity and quality of life in patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomised, placebo-controlled trial. Eur Respir J. 2019. PMID: 31073087. doi:10.1183/13993003.002762019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。